BRAEGEN PHARMACEUTICAL
Braegen Pharmaceutical Company, is based in China. The company is developing drugs for neurodegenerative diseases including Alzheimer’s disease. The Emory intellectual property licensed to the company relates to a series of small molecule precursors to7, 8-dihydroxyflavone (7, 8 DHF), a potent tyrosine receptor kinase B (TrkB) agonist, for the treatment of various neurological diseases.
BRAEGEN PHARMACEUTICAL
Industry:
Biotechnology Health Care Pharmaceutical
Address:
Atlanta, Georgia, United States
Country:
United States
Status:
Active
Similar Organizations
Neuromagen Pharma
Neuromagen Pharma develops drugs for neurodegenerative diseases including ALS.
Synaps Dx
Synaps Dx focuses on the research, development and commercialization for neurodegenerative disorders including Alzheimer’s Disease.
More informations about "Braegen Pharmaceutical"
Braegen Company Profile 2024: Valuation, Funding & Investors
Braegen General Information Description. Developer of drug research and development platform intended to promote human health. The company targets neurodegenerative diseases in …See details»
Braegen Pharmaceuticals - Funding, Financials, Valuation & Investors
Nov 19, 2024 Braegen Pharmaceuticals has raised 1 round. This was a Series A round raised on Nov 19, 2024. Braegen Pharmaceuticals is funded by 3 investors. TusStar and Cowin …See details»
Braegen Pharmaceutical Co. - Drug pipelines, Patents, Clinical trials ...
Explore Braegen Pharmaceutical Co. with its drug pipeline, therapeutic area, technology platform, , Disease Domain:Nervous System Diseases, Endocrinology and Metabolic Disease, …See details»
Braegen Pharmaceuticals - Tech Stack, Apps, Patents & Trademarks
Braegen Pharmaceuticals is a novel medicine development and research organization focused on cutting-edge research. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. …See details»
Shanghai Braegen Pharmaceuticals - Overview, News & Similar
Shanghai Braegen Pharmaceuticals is a company that operates in the Pharmaceuticals industry. It employs 21-50 people and has $5M-$10M of revenue. T he company is headquartered in …See details»
Shanghai Braegen Pharmaceuticals Co. Ltd. - BioCentury
Shanghai Braegen Pharmaceuticals Co. Ltd. - BioCentury Company Profiles for the biopharma industrySee details»
Drug Discovery Companies | Emory University | Atlanta GA
Company Profile: Shanghai Braegen Pharmaceutical is developing drugs for neurodegenerative diseases including Alzheimer's disease. Their focus is on a TrkB receptor for brain-derived …See details»
Braegen-04 - Drug Targets, Indications, Patents - Synapse
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.See details»
Braegen-05 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.See details»
Series A - Braegen Pharmaceuticals - 2024-11-19 - Crunchbase
Nov 19, 2024 Organization Name . Braegen Pharmaceuticals . Announced Date Nov 19, 2024; Funding Type Series A; Funding Stage Early Stage Venture; Lead Investors. Edit Lead …See details»
Spying on α-Synuclein Inclusions: PET Tracers Inch Closer
Aug 4, 2023 Braegen Pharmaceuticals, Ltd., a company in Shanghai co-founded by Ye, sponsors development. Signaling Synucleinopathy. PET scans display 18F-F0502B retention …See details»
Braegen Pharmaceuticals - Crunchbase
Companies like Braegen Pharmaceuticals include Merck, SYMAX, and Bridge Pharmaceuticals. Bridge Pharmaceuticals . Gaithersburg, Maryland, United States 1-10 employees . …See details»
Wuhan Yuanzheng Century Pharmaceutical Co., Ltd.
Explore Wuhan Yuanzheng Century Pharmaceutical Co., Ltd. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, Disease Domain:Nervous System Diseases, …See details»
Braegen Pharmaceutical - Crunchbase
The company is developing drugs for neurodegenerative diseases including Alzheimer’s disease.See details»
CF3CN - Drug Targets, Indications, Patents - Synapse - Patsnap
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.See details»
Development of an α-synuclein positron emission tomography
Declaration of interests K.Y. is a co-founder of Shanghai Braegen Pharmaceuticals, Inc. that licensed the PET tracer patent from Emory University. No data are sponsored by the …See details»
Braegen-03 - Drug Targets, Indications, Patents - Synapse - Patsnap
PURPOSE To investigate the effects of aquatic exercise programs (AEP) in body structure and function, activity, and participation outcomes in individuals with Parkinson's disease (PD) with …See details»
NeuroGenetic Pharmaceuticals - Crunchbase
Apellis, Idera, Adamas, and Arrowhead focus on developing novel therapeutics and drug delivery technologies for various diseases, while Braegen Pharmaceutical specifically targets …See details»
BrAD-R13 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 30, 2024 Radiation induced BDNF-TrkB signaling dysregulation and decreased the levels of neuron-related functional genes (Ngf, Bdnf, Gap-43, Ras, Psd-95, Arc, Creb, c-Fos), PSD-95 …See details»